134 related articles for article (PubMed ID: 31444972)
1. Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.
Nome ME; Euceda LR; Jabeen S; Debik J; Bathen TF; Giskeødegård GF; Taskén KA; Maelandsmo GM; Halvorsen B; Yndestad A; Borgen E; Garred Ø; Aukrust P; Ueland T; Engebraaten O; Kristensen VN; Tekpli X
Int J Cancer; 2020 Jan; 146(1):223-235. PubMed ID: 31444972
[TBL] [Abstract][Full Text] [Related]
2. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Makhoul I; Griffin RJ; Siegel E; Lee J; Dhakal I; Raj V; Jamshidi-Parsian A; Klimberg S; Hutchins LF; Kadlubar S
Am J Clin Oncol; 2016 Jun; 39(3):248-54. PubMed ID: 24577164
[TBL] [Abstract][Full Text] [Related]
3. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
[TBL] [Abstract][Full Text] [Related]
4. Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.
Haugen MH; Lingjærde OC; Hedenfalk I; Garred Ø; Borgen E; Loman N; Hatschek T; Børresen-Dale AL; Naume B; Mills GB; Mælandsmo GM; Engebraaten O
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036235
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
Etxano J; Insausti LP; Elizalde A; López Vega JM; Plazaola A; Martínez P
Acta Radiol; 2015 Nov; 56(11):1300-7. PubMed ID: 25348477
[TBL] [Abstract][Full Text] [Related]
6. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
[TBL] [Abstract][Full Text] [Related]
7. The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.
Silwal-Pandit L; Nord S; von der Lippe Gythfeldt H; Møller EK; Fleischer T; Rødland E; Krohn M; Borgen E; Garred Ø; Olsen T; Vu P; Skjerven H; Fangberget A; Holmen MM; Schlitchting E; Wille E; Nordberg Stokke M; Moen Vollan HK; Kristensen V; Langerød A; Lundgren S; Wist E; Naume B; Lingjærde OC; Børresen-Dale AL; Engebraaten O
Clin Cancer Res; 2017 Aug; 23(16):4662-4670. PubMed ID: 28487444
[No Abstract] [Full Text] [Related]
8. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
10. Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.
Höglander EK; Nord S; Wedge DC; Lingjærde OC; Silwal-Pandit L; Gythfeldt HV; Vollan HKM; Fleischer T; Krohn M; Schlitchting E; Borgen E; Garred Ø; Holmen MM; Wist E; Naume B; Van Loo P; Børresen-Dale AL; Engebraaten O; Kristensen V
Genome Med; 2018 Nov; 10(1):92. PubMed ID: 30497530
[TBL] [Abstract][Full Text] [Related]
11. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
12. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Tabouret E; Bertucci F; Pierga JY; Petit T; Levy C; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; van Laere S; Ueno NT; Toiron Y; Finetti P; Birnbaum D; Borg JP; Viens P; Chinot O; Gonçalves A
Oncotarget; 2016 Apr; 7(14):18531-40. PubMed ID: 26921265
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
[TBL] [Abstract][Full Text] [Related]
14. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
15. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
[TBL] [Abstract][Full Text] [Related]
16. Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy.
Litviakov N; Tsyganov M; Larionova I; Ibragimova M; Deryusheva I; Kazantseva P; Slonimskaya E; Frolova I; Choinzonov E; Cherdyntseva N; Kzhyshkowska J
Cancer Chemother Pharmacol; 2018 Jul; 82(1):99-109. PubMed ID: 29728799
[TBL] [Abstract][Full Text] [Related]
17. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Janning M; Müller V; Vettorazzi E; Cubas-Cordova M; Gensch V; Ben-Batalla I; Zu Eulenburg C; Schem C; Fasching PA; Schnappauf B; Karn T; Fehm T; Just M; Kühn T; Holms F; Overkamp F; Krabisch P; Rack B; Denkert C; Untch M; Tesch H; Rezai M; Kittel K; Pantel K; Bokemeyer C; Loibl S; von Minckwitz G; Loges S
Int J Cancer; 2019 Aug; 145(3):857-868. PubMed ID: 30694523
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
Cao L; Yao GY; Liu MF; Chen LJ; Hu XL; Ye CS
PLoS One; 2015; 10(12):e0145442. PubMed ID: 26717149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
